Citius Pharmaceuticals, Inc. (43)
Browse by Contract Category
Contracts
-
Description of Common Stock
(Filed With SEC on December 22, 2022)
-
Amended and Restated Employment Agreement between Myron Holubiak and Citius Pharmaceuticals, Inc., dated April 12, 2022 and effective May 1, 2022
(Filed With SEC on May 12, 2022)
-
Amendment No. 2 to Amended and Restated License, Development and Commercialization Agreement, dated as of August 31, 2021, between Eisai, Ltd. and Dr. Reddys Laboratories S.A
(Filed With SEC on December 15, 2021)
-
Engagement letter, dated January 23, 2021, between Citius Pharmaceuticals, Inc. and H. C. Wainwright & Co., LLC
(Filed With SEC on January 27, 2021)
-
Amendment to Amended and Restated License, Development and Commercialization Agreement, dated as of August 9, 2018, between Eisai, Ltd. and Dr. Reddys Laboratories S.A
(Filed With SEC on December 15, 2021)
-
Amended and Restated License, Development and Commercialization Agreement, dated as of February 26, 2018, between Eisai, Ltd. and Dr. Reddys Laboratories S.A
(Filed With SEC on December 15, 2021)
-
Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddys Laboratories S.A. and Citius Pharmaceuticals, Inc
(Filed With SEC on December 15, 2021)
-
Form of Notice of Stock Option Grant and Stock Option Award Agreement
(Filed With SEC on December 15, 2021)
-
Form of placement agent warrant issued February 19, 2021
(Filed With SEC on February 19, 2021)
-
Form of investor warrant issued February 19, 2021
(Filed With SEC on February 19, 2021)
-
Form of Securities Purchase Agreement, dated February 16, 2021, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto
(Filed With SEC on February 19, 2021)
-
Form of Securities Purchase Agreement, dated January 24, 2021, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto
(Filed With SEC on January 27, 2021)
-
Form of Registration Rights Agreement, dated January 24, 2021, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto
(Filed With SEC on January 27, 2021)
-
Form of placement agent warrant issued January 27, 2021
(Filed With SEC on January 27, 2021)
-
Form of investor warrant issued January 27, 2021
(Filed With SEC on January 27, 2021)
-
License Agreement, dated October 6, 2020, between NoveCite, Inc. and Novellus Therapeutics, Limited
(Filed With SEC on December 16, 2020)
-
Employment Agreement, effective as of July 14, 2020, between Citius Pharmaceuticals, Inc. and Myron Czuczman
(Filed With SEC on August 14, 2020)
-
Form of Underwriter Warrant
(Filed With SEC on August 10, 2020)
-
Amended and Restated Underwriting Agreement between Citius Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC, dated as of August 5, 2020
(Filed With SEC on August 10, 2020)
-
Form of Securities Purchase Agreement, dated May 14, 2020, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto
(Filed With SEC on May 18, 2020)
-
Engagement letter, dated February 14, 2020, between Citius Pharmaceuticals, Inc. and H. C. Wainwright & Co., LLC
(Filed With SEC on May 18, 2020)
-
Form of placement agent warrant issued May 18, 2020
(Filed With SEC on May 18, 2020)
-
Form of investor warrant issued May 18, 2020
(Filed With SEC on May 18, 2020)
-
Form of Warrant Exercise Agreement, dated February 14, 2020, by and between Citius Pharmaceuticals, Inc. and the investor signatory thereto
(Filed With SEC on February 19, 2020)
-
Form of Warrant Exercise Agreement, dated February 14, 2020, by and between Citius Pharmaceuticals, Inc. and the investor signatory thereto
(Filed With SEC on February 19, 2020)
-
Form of Placement Agent Warrant issued on February 19, 2020
(Filed With SEC on February 19, 2020)
-
Form of Investor Warrant issued on February 19, 2020
(Filed With SEC on February 19, 2020)
-
Form of Notice of Stock Option Grant and Stock Option Award Agreement
(Filed With SEC on February 13, 2020)
-
Form of Underwriters Common Stock Purchase Warrant issued on September 27, 2019
(Filed With SEC on September 27, 2019)
-
Underwriting Agreement, dated as of September 25, 2019, by and between Citius Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC
(Filed With SEC on September 27, 2019)
-
Form of Common Stock Purchase Warrant issued on September 27, 2019
(Filed With SEC on September 27, 2019)
-
Form of Pre-Funded Common Stock Purchase Warrant issued on September 27, 2019
(Filed With SEC on September 27, 2019)
-
Form of Underwriting Agreement
(Filed With SEC on September 20, 2019)
-
Form of Common Stock Purchase Warrant
(Filed With SEC on September 20, 2019)
-
Form of Pre-Funded Common Stock Purchase Warrant
(Filed With SEC on September 20, 2019)
-
Form of Underwriters Common Stock Purchase Warrant
(Filed With SEC on September 20, 2019)
-
Form of investor warrant
(Filed With SEC on April 3, 2019)
-
Engagement letter, dated March 22, 2019, between Citius Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC
(Filed With SEC on April 3, 2019)
-
Form of Securities Purchase Agreement, dated April 1, 2019, by and between Citius Pharmaceuticals, Inc. and the purchasers named therein
(Filed With SEC on April 3, 2019)
-
Form of placement agent warrant
(Filed With SEC on April 3, 2019)
-
First Amendment, dated October 15, 2015, to Patent and Technology License Agreement, dated May 14, 2014, between Novel Anti-Infective Technologies, LLC and Leonard-Meron...
(Filed With SEC on February 14, 2019)
-
Patent and Technology License Agreement, dated May 14, 2014, between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc
(Filed With SEC on February 14, 2019)
-
Patent and Technology License Agreement, dated January 2, 2019, between the Board of Regents of the University of Texas System on behalf of the University of Texas M. D. Anderson...
(Filed With SEC on February 14, 2019)